A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy In Vivo

Journal of Virology

Volumn 86, Issue 11, 2012, Pages 6179-6188

  Tan, Gene S ^a   Krammer, Florian ^a   Eggink, Dirk ^a   Kongchanagul, Alita ^a   Moran, Thomas M ^a   Palese, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6F12; UNCLASSIFIED DRUG; HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY ISOLATION; ANTIGENICITY; ANTIVIRAL ACTIVITY; ARTICLE; B LYMPHOCYTE; DRUG CROSS REACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYBRIDOMA CELL CULTURE; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA VIRUS A; MOUSE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; VIRUS HEMAGGLUTINATION; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; CROSS REACTION; DISEASE MODEL; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; ISOLATION AND PURIFICATION; ORTHOMYXOVIRUS INFECTION; PASSIVE IMMUNIZATION; PATHOLOGY;

INFLUENZA A VIRUS; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BODY WEIGHT; CROSS REACTIONS; DISEASE MODELS, ANIMAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION, PASSIVE; INFLUENZA A VIRUS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84863597077     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00469-12     Document Type: Article

References (36)

1. Beigel J, Bray M. 2008. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 78:91-102.
2. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. 1994. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371:37-43.
3. Chen J, Skehel JJ, Wiley DC. 1999. N- and C-terminal residues combine in the fusion-pH influenza hemagglutinin HA(2) subunit to form an N cap that terminates the triple-stranded coiled coil. Proc. Natl. Acad. Sci. U. S. A. 96:8967-8972.
4. Corti D, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850-856.
5. Ekiert DC, et al. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251.
6. Ekiert DC, et al. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843-850.
7. Graves PN, Schulman JL, Young JF, Palese P. 1983. Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 126:106-116.
8. Harrison SC. 2008. Viral membrane fusion. Nat. Struct. Mol. Biol. 15:690-698.
9. Jungbauer A, et al. 1989. Comparison of protein A, protein G and copolymerized hydroxyapatite for the purification of human monoclonal antibodies. J. Chromatogr. 476:257-268.
10. Krammer F, et al. 2010. Swine-origin pandemic H1N1 influenza viruslike particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice. Biotechnol. J. 5:17-23.
11. Krause JC, et al. 2011. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J. Virol. 85:10905-10908.
12. Lowen AC, Palese P. 2007. Influenza virus transmission: basic science and implications for the use of antiviral drugs during a pandemic. Infect. Disord. Drug Targets 7:318-328.
13. Luxembourg A, Evans CF, Hannaman D. 2007. Electroporation-based DNA immunisation: translation to the clinic. Expert. Opin. Biol. Ther. 7:1647-1664.
14. Luxembourg A, et al. 2008. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 26:5216-5222.
15. Manicassamy B, et al. 2010. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog. 6:e1000745.
16. Memoli MJ, et al. 2009. An early 'classical' swine H1N1 influenza virus shows similar pathogenicity to the 1918 pandemic virus in ferrets and mice. Virology 393:338-345.
17. Miyazaki J, et al. 1989. Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene 79:269-277.
18. Moran T, Liu YC, Schulman JL, Bona CA. 1984. Shared idiotopes among monoclonal antibodies specific for A/PR/8/34 (H1N1) and X-31(H3N2) influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 81:1809-1812.
19. Okuno Y, Matsumoto K, Isegawa Y, Ueda S. 1994. Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J. Virol. 68:517-520.
20. Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67:2552-2558.
21. O'Neill RE, Talon J, Palese P. 1998. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins.EMBOJ. 17:288-296.
22. Palese P, Wang TT. 2011. Why do influenza virus subtypes die out? A hypothesis. mBio 2(5):00150-11. doi:10.1128/mBio.00150-11.
23. Palese P, Shaw ML. 2006. Orthomyxoviridae: the viruses and their replication, p 1647-1689. In Knipe DM, et al (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
24. Pica N, et al. 2012. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl. Acad. Sci. U. S. A. 109:2573-2578.
25. Pica N, et al. 2011. The DBA.2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza A and B viruses. J. Virol. 85:12825-12829.
26. Reale MA, et al. 1986. Characterization of monoclonal antibodies specific for sequential influenza A/PR/8/34 virus variants. J. Immunol. 137:1352-1358.
27. Smirnov YA, Lipatov AS, Gitelman AK, Claas EC, Osterhaus AD. 2000. Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in theHAstem region. Arch. Virol. 145:1733-1741.
28. Smith DJ, et al. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305:371-376.
29. Smith JH, et al. 2011. Comparative pathology in ferrets infected with H1N1 influenza A viruses isolated from different hosts. J. Virol. 85:7572-7581.
30. Steel J, et al. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio. 1(1):e00018-10. doi:10.1128/mBio.00018-11.
31. Sui J, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273.
32. Throsby M, et al. 2008. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3:e3942.
33. Wang TT, et al. 2010. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 6:e1000796.
34. World Health Organization. 2003. Factsheet 211: influenza. World Health Organization, Geneva, Switzerland.
35. Wrammert J, et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208:181-193.
36. Xu R, et al. 2010. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328:357-360.